Establishment of a novel IFN therapy with little side effects
Establishment of a novel IFN therapy with little side effects
批准号:
17390277
负责人:
ORITANI Kenji
金额:
$9.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2006
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Our identified IFN-ζ/Limitin has similar anti-viral and immunomoduratory activities to IFN-a. However, IFN-ζ/Limitin failed to suppress colony formation of CFU-GM, BFU-E, and CFU-Meg. Although less myelo-suppressive property may suggest wide range of clinical utility of IFN-ζ/Limitin, human homologue of IFN-ζ/Limitin has not been identified yet. There are unique amino acid residues in receptor-binding sites of IFN-ζ/Limitin when compared with IFN-α and IFN-β. To identify responsible amino acid residues for the different biological activities between IFN-t/Lmitin and IFN-α, we constructed several mutated IFN-α (ml-m7-IFN-a) whose amino acid residues were substituted by those of IFN-ζ/Limitin, and compared biological activities of the mutated IFN-as with those of original IFN-α. m3-IFN-α carrying three amino acids substitution in the AB loop has revealed less suppressive effects on colony formation of CFU-GM and BFU-E, while it has similar anti-viral activity to IFN-α. Little myelo-suppr … More essive property of m3-IFN-α was also confirmed by the injection to mice. On the other hand, ml-IFN-α carrying four amino acids substitution in the herix C has revealed higher anti-viral activity than original IFN-α. The other mutated IFN-αs lost both anti-viral and myelo-suppressive activities. These results are useful to construct a novel human IFN, which has IFN-ζ/Limitin-like characters.We have analyzed IFN-signals, which mediate myelo-suppressive activities, and have clarified essential roles of Tyk2 and Daxx. Reduction of protein expression of Tyk2 and/or Daxx by antisense oligonucleotides resulted in lack of myelo-suppressive activities of IFN-α. In addition, a sumoylation-defective Daxx KA mutant (Daxx K630/631A) localized in the cytoplasm, whereas wild-type Daxx localized in the nucleus. Murine pro-B cell line Ba/F3 expressing Daxx KA revealed a resistance to IFN-induced growth suppression, indicating the important role of sumoylation of Daxx in IFN-induced myelo-suppression. These results are useful to design a strategy for the IFN-therapy. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2005
期刊:
Journal of cellular and molecular medicine
影响因子:
5.3
作者:
[K. Oritani;Y. Kanakura]
通讯作者:
K. Oritani;Y. Kanakura
Differential effects of a novel IFN-zeta/limitin and IFN-alphs on signals for Daxx induction and Crk phosphorylation that couple with growth control of megakaryocytes.
新型 IFN-zeta/limitin 和 IFN-α 对 Daxx 诱导和 Crk 磷酸化信号的不同影响,与巨核细胞的生长控制相结合。
DOI:
--
发表时间:
2005
期刊:
Exp Hematol 33(4)
影响因子:
--
作者:
[Oritani K, et al., Oritani K et al., Ishida N et al.]
通讯作者:
Ishida N et al.
DOI:
10.1038/sj.onc.1209235
发表时间:
2006-03-01
期刊:
ONCOGENE
影响因子:
8
作者:
[Muromoto, R, Nakao, K, Matsuda, T]
通讯作者:
Matsuda, T
DOI:
10.1002/jcb.20779
发表时间:
2006-05
期刊:
Journal of Cellular Biochemistry
影响因子:
4
作者:
[H. Ujiie;K. Oritani;H. Kato;T. Yokota;Isao Takahashi;T. Maeda;H. Masaie;M. Ichii;Y. Kamada;S. Tamura;S. Kihara;T. Funahashi;Y. Tomiyama;Y. Kanakura]
通讯作者:
H. Ujiie;K. Oritani;H. Kato;T. Yokota;Isao Takahashi;T. Maeda;H. Masaie;M. Ichii;Y. Kamada;S. Tamura;S. Kihara;T. Funahashi;Y. Tomiyama;Y. Kanakura
DOI:
10.4049/jimmunol.176.1.380
发表时间:
2006-01-01
期刊:
JOURNAL OF IMMUNOLOGY
影响因子:
4.4
作者:
[Sekine, Y, Yumioka, T, Matsuda, T]
通讯作者:
Matsuda, T
共 6 条
Analysis of in vivo effects of possible immune regulatory moleculesfor artificial management of immune systems
-
批准号:22591062
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2010
-
负责人:ORITANI Kenji
-
依托单位:
Development of a novel interferon with mild adverse effects
-
批准号:19390264
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.98万
-
财政年份:2007
-
负责人:ORITANI Kenji
-
依托单位:
Difference of biological activities and signals between IFN-ζ/limitin and IFN-α
-
批准号:15390300
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$9.47万
-
财政年份:2003
-
负责人:ORITANI Kenji
-
依托单位:
Biological activity of limitin and adiponectin
-
批准号:13671064
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.56万
-
财政年份:2001
-
负责人:ORITANI Kenji
-
依托单位:
Clinical application of limitin that has anti-tumor and anti-viral activity
-
批准号:13557081
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$8.9万
-
财政年份:2001
-
负责人:ORITANI Kenji
-
依托单位:
国内基金
海外基金
登录
查看更多内容
系统性探索不同N-glycan修饰对Interferonβ活性和稳定性影响
-
批准号:21877063
-
项目类别:面上项目
-
资助金额:61.4万元
-
批准年份:2018
-
负责人:王鹏
-
依托单位:
控制肠道病毒71型感染的先天性免疫保护机制及其应用
-
批准号:31270951
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:冷启彬
-
依托单位:
干扰素信号分子及其调控网络在抗HBV感染过程中的作用机制研究
-
批准号:81171558
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2011
-
负责人:宁琴
-
依托单位:
糖药物蛋白Interferonβ N-glycan的均一、人源化改造
-
批准号:81102361
-
项目类别:青年科学基金项目
-
资助金额:25.0万元
-
批准年份:2011
-
负责人:程剑松
-
依托单位:
T细胞识别的鳞状细胞癌1型抗原增强干扰素-α抗丙型肝炎病毒作用的研究
-
批准号:81170386
-
项目类别:面上项目
-
资助金额:45.0万元
-
批准年份:2011
-
负责人:赵鸿
-
依托单位:
转录因子Ets2对TLR介导的I型干扰素及IL27表达的调节作用
-
批准号:30971510
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2009
-
负责人:张燕
-
依托单位:
神经胶质成熟因子-β对肝星状细胞活化和肝纤维化的影响及其机制研究
-
批准号:30800508
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:饶慧瑛
-
依托单位:
ICP34.5结构和功能的关系及其对宿主免疫系统的影响
-
批准号:30670080
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2006
-
负责人:曹又佳
-
依托单位: